应用PD-1抑制剂后高血糖症1例

程序性细胞死亡蛋白1（PD-1）的单克隆抗体可以阻断PD-1与其配体之间的相互作用,恢复T细胞的抗肿瘤作用。PD-1抑制剂已被广泛批准用于治疗各种恶性肿瘤。有大量文献报道了信迪利单抗有令人满意的抗肿瘤作用,同时也报道出一些相关不良反应。由PD-1抑制剂引起的急性自身免疫性胰岛素依赖型糖尿病在儿童中非常罕见。现报道广东药科大学附属第一医院2021年11月收治的1例应用PD-1抗体后出现高血糖症儿童。

1 case of hyperglycemia caused by PD-1 inhibitors

The monoclonal antibody of programmed cell deathprotein 1 (PD-1) can block the interaction between PD-1 and its ligand,meanwhile also restore the anti-tumor immunity of T cells. PD-1 inhibitors areapproved widely for the treatment of various types of malignancies. A largenumber of literatures have explained the excellent anti-tumor effects ofSindilizumab as well as some side effects. But it is very rare to see acuteautoimmune insulin-dependent diabetes mellitus caused by PD-1 inhibitors inchildren. We now report one child with hyperglycemia after using PD-1inhibitors in The First Affiliated Hospital of Guangdong PharmaceuticalUniversity in November 2021.